Abstract
GnRH analogues suppress LH fluctuations and produce a condition of hypogonadotropic hypogonadism. This action combined with treatment with human menopausal gonadotropins (hMG) has been exploited in programmes of induction of follicular growth in infertile women for both in vivo and in vitro fertilisation. There is improved clinical control over the process of ovulation and the phenomenon of premature luteinization in women with polycystic ovary disease has been eliminated.
MeSH terms
-
Drug Therapy, Combination
-
Female
-
Fertilization in Vitro
-
Gonadotropin-Releasing Hormone / administration & dosage
-
Gonadotropin-Releasing Hormone / analogs & derivatives*
-
Gonadotropin-Releasing Hormone / therapeutic use
-
Humans
-
Infertility, Female / drug therapy*
-
Infertility, Female / etiology
-
Insemination, Artificial
-
Menotropins / administration & dosage
-
Menotropins / therapeutic use*
-
Oocytes / transplantation
-
Ovulation Induction
-
Polycystic Ovary Syndrome / complications
-
Pregnancy
Substances
-
Gonadotropin-Releasing Hormone
-
Menotropins